Product Overview
5-Amino-1-methylquinolinium, shortened to 5-Amino-1MQ or 5A-1MQ, is a small synthetic molecule rather than a peptide, although it is shelved among peptides here. Generic Peptides lists it as freeze-dried powder in 10 mg and 50 mg fills. Its target is nicotinamide N-methyltransferase, the enzyme known as NNMT, which transfers a methyl group from SAM onto nicotinamide to make 1-MNA.
Inhibiting that reaction has two consequences inside a cell. More SAM remains available for other methylation work, and more NAD+ stays in circulation because less of it is consumed in the pathway around NNMT. In cultured adipocytes the result is reduced fat formation, and in living mice the published work describes a leaner animal. An observational angle reinforces the interest: NNMT activity correlates with obesity and type 2 diabetes in human tissue studies, which is a correlation and not proof that blocking the enzyme helps anyone.
The compound was characterised in 2018 as a selective inhibitor that leaves related SAM-dependent methyltransferases and NAD+ enzymes alone, and a second study in 2022 repeated the metabolic findings in a different model. That is the whole published base, and all of it is preclinical.
Dosage Protocol
There are no human figures of any kind, so the only quantities that can be written are the animal protocol and the arithmetic of dilution. Neither is a schedule for a person.
| Animal reference | 32 mg per kg of body weight under the skin each day in the 2022 diet-induced obesity model |
| Route in models | Subcutaneous injection, chosen partly because oral absorption in rodents is poor |
| 10 mg plus 1 ml | Reaches 10 mg/ml, where a 10 unit pull carries 1 mg |
| 10 mg plus 2 ml | Halves it to 5 mg/ml and a 500 mcg pull at the same mark |
| 50 mg plus 5 ml | Returns to 10 mg/ml and a 1 mg pull |
| 50 mg plus 10 ml | Returns to 5 mg/ml and a 500 mcg pull, so both fills can be matched |
| Female | No separate protocol is described in any source checked |
Bacteriostatic water is run down the inside of the vial and the contents are left to dissolve without shaking. Dry powder keeps cold at 2-8 C, and the made-up solution is also kept at 2-8 C and never frozen; as a small molecule it is generally more robust than a peptide, though the seller publishes nothing specific about solution stability. Because the mouse work dosed daily, the interval between administrations was evidently short, and that is as much as can honestly be inferred about timing in people.
Suggested Protocols
No study has combined this compound with anything else sold here, so the groupings below are shelf comparisons rather than a regimen. They separate the metabolic compounds that work through cellular energy handling, the fat-loss products bought for the same reason, and the redox agent that pairs most naturally on paper.
What to Expect
- No human data exist. There are no published clinical trials of this compound in people, which puts it a step behind almost everything else on this shelf.
- Leaner mice on the same food. In diet-induced obese animals the treatment lowered body mass, white fat mass, adipocyte size and total plasma cholesterol while food intake stayed unchanged.
- Not an appetite effect. Since the animals ate the same amount, the weight change in the model cannot be explained by eating less, which is the opposite of how an incretin works.
- A methylation mechanism. Inhibiting NNMT leaves more SAM and more NAD+ inside cells and suppresses lipogenesis in cultured adipocytes, which is the pathway the whole claim rests on.
- Liver findings in the second model. The 2022 study reported normalised fat mass and liver pathology at a time when diet alone had not produced that result, which is a model observation rather than a human one.
- Correlation is not causation. Human tissue studies link NNMT activity with obesity and type 2 diabetes, but that does not demonstrate that an inhibitor changes the disease.
Side Effects and Management
With no human study to draw on, the list below is built from the mechanism and from the ordinary risks of an injected research solution. Every row is unconfirmed in people.
Post-Cycle Therapy
This molecule has no steroidal action at all, so a recovery protocol is not applicable and is not invented here. It does not suppress the gonadal axis, does not raise oestrogen and does not affect sperm production or natural testosterone output.
Athletes should note the status rather than the chemistry. 5-Amino-1MQ is not named on the prohibited list, but because it is not an approved medicine anywhere it can fall under the general category for non-approved substances, which makes an unlisted status a risk rather than a permission.
